Vancouver, Canada

Shafique Fidai


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovator Shafique Fidai: Pioneering Cancer Treatments

Introduction

Shafique Fidai is a notable inventor based in Vancouver, CA, with a remarkable focus on developing advanced therapies for cancer treatment. With two patents to his name, his contributions are recognized for their potential impact on immunotherapy.

Latest Patents

Fidai's latest patents involve IL-2 superagonists in combination with anti-PD-1 antibodies. He has developed human interleukin-2 (IL-2) muteins, which show an increased binding capacity for the IL-2Rβ receptor compared to the wild-type IL-2. These innovations aim to enhance the efficacy of combination therapies with anti-PD-1 antibodies for cancer treatment. Furthermore, his patents also encompass pharmaceutical compositions that include these IL-2 muteins alongside the anti-PD-1 antibodies, presenting a significant advancement in the field of oncological therapeutics.

Career Highlights

Fidai currently works at Medicenna Therapeutics, Inc., where he focuses on novel approaches to immuno-oncology. His career is characterized by a commitment to science and a drive to improve patient outcomes through innovative therapeutic solutions. Alongside his coworker, Fahar Merchant, Fidai contributes to the company's mission of developing impactful treatments.

Collaborations

In his role at Medicenna Therapeutics, Fidai collaborates with a team of dedicated scientists and professionals, including Fahar Merchant. Together, they are focused on pushing the boundaries of cancer treatment through groundbreaking research and development.

Conclusion

Shafique Fidai exemplifies the spirit of innovation in the biomedical field. With his significant patents and ongoing collaborations, his work continues to pave the way for advancements in the treatment of cancer, offering hope for more effective therapeutic options in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…